Shots:
- The US FDA has granted 510(k) clearance & CLIA waiver for Cobas liat STI multiplex assay panels (CT/NG & CT/NG/MG), commercially available under the CE mark in upcoming months
- The CT/NG (chlamydia & gonorrhea) & CT/NG/MG (chlamydia, gonorrhea & Mycoplasma genitalium) assays compliment the existing portfolio of singleplex & multiplex tests of Cobas liat for a variety of pathogens incl. SARS-CoV-2, influenza A/B, Strep A., & C. diff
- These panels enable easy & rapid diagnoses of multiple STIs with a single sample using gold-standard PCR technology to produce the results within ≤20 min
Ref: Globenewswire | Image: Roche
Related News:- Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
